ClinicalTrials.gg
CompletedNCT07231029Updated Nov 9, 2026

A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment

A Phase 1 interventional study of TS-172 in Patients With Mild or Moderate Hepatic Impairment, sponsored by Taisho Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Taisho Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Updated Nov 9, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

An open-label study to evaluate the effect of TS-172 administration on pharmacokinetics in patients with hepatic impairment

02

Conditions studied

  • Patients With Mild or Moderate Hepatic Impairment
03

In context

Lead sponsor

Taisho Pharmaceutical Co., Ltd. is the lead sponsor of 43 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

\<Inclusion criteria for patients with hepatic impairment>

  1. Japanese male and female patients whose age is >=18 and \<=75 years at the time of obtaining
  2. Patients with chronic hepatic impairment
  3. Patients who were classified by the principal investigator or sub-investigator as Class A (mild) or Class B (moderate) by classification at the screening test Other protocol defined inclusion criteria could apply.

\<Inclusion criteria for subjects with normal hepatic function>

  1. Japanese male and female patients whose age is >=18 and \<=75 years at the time of obtaining informed consent
  2. Subjects whose is >=18.5 and \<35.0 at the screening test Other protocol defined inclusion criteria could apply.

\<Exclusion criteria for patients with hepatic impairment>

  1. Patients with medical history of liver resection or liver transplantation
  2. Patients with grade II or higher hepatic encephalopathy
  3. Patients whose is \<45 mL/min/1.73 m2 at screening test Other protocol defined exclusion criteria could apply.

\<Exclusion criteria for subjects with normal hepatic function>

  1. Subjects with current condition or medical history of diseases that are ineligible for participation in the study
  2. Subjects whose eGFR is \<60 mL/min/1.73 m2 at screening test Other protocol defined exclusion criteria could apply.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    Mild hepatic impairment

    Drug: TS-172

  • Experimental
    Moderate hepatic impairment

    Drug: TS-172

  • Experimental
    Normal hepatic function

    Drug: TS-172

Interventions

  • DrugTS-172

    Single oral administration of TS-172 20mg

06

What researchers measure

Primary outcomes

  1. Plasma concentrations of unchanged form and metabolites

    Time frame: Up to 48 hours after dosing

07

Study locations

1 site
  • Taisho Pharmaceutical Co., Ltd selected site
    Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2025 to primary completion in Oct 2026, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 17, 2025
StartActual
Dec 23, 2025
Primary completionActual
Oct 21, 2026
CompletionActual
Oct 26, 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 9, 2026
Primary completion
Oct 26, 2026→Oct 21, 2026 (actual)
Nov 9, 2026
Study completion
Oct 31, 2026→Oct 26, 2026 (actual)
Nov 9, 2026
Enrollment
24 (estimated)→25 (actual)
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Recruiting→Completed
    Primary completion Oct 26, 2026→Oct 21, 2026 (now actual)
    Study completion Oct 31, 2026→Oct 26, 2026 (now actual)
    Enrollment 24 (estimated)→25 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07231029
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Dec 23, 2025
Primary completion
Oct 21, 2026
Completion
Oct 26, 2026
Last update
Nov 9, 2026

Study contacts

Taisho Director Taisho Director
study director · Taisho Pharmaceutical Co., Ltd.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TS-172

Start the discussion